RxDoctor Payments DataLook up a doctor →

William Merritt, MD

Gynecologic Oncology · Columbia, SCNPI 1609070143

Payments from drug & device makers

$8,592in general payments, 2019–2025

Across 379 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$850
  • AstraZeneca$691
  • Johnson & Johnson$675
  • Takeda Pharmaceuticals U.S.A., Inc.$434
  • Myriad Genetic Laboratories, Inc.$385
  • Merck$338
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,35797%
  • Education$330%
  • Gifts$2032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,826,428
Medicare patients
510
Services billed
176,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate25$444,073
RubracaRucaparib Camsylate36$405,792
LenvimaLenvatinib Mesylate17$375,314
LynparzaOlaparib14$216,110
EliquisApixaban47$30,516
Megestrol Acetate16$928
Ondansetron OdtOndansetron77$770
Letrozole52$564
Dexamethasone43$554
Potassium Chloride25$314
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$255
Prochlorperazine Maleate30$228
Oxycodone Hcl20$153
Methadone Hcl12$143
Tramadol Hcl49$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$101$444,07325 claims
Clovis Oncology, Inc.Rubraca$32$405,79236 claims
Eisai Inc.Lenvima$224$375,31417 claims
AstraZenecaLynparza$691$216,11014 claims
PfizerEliquis$287$30,51647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other gynecologic oncology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →